Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist
Autore:
Herbert, JM; Savi, P; Maffrand, JP;
Indirizzi:
Sanofi Rech, Haemobiol Res Dept, F-31036 Toulouse, France Sanofi Rech Toulouse France F-31036 l Res Dept, F-31036 Toulouse, France
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: A, volume: 1, anno: 1999,
pagine: A31 - A40
SICI:
1520-765X(199902)1:A<A31:BAPPOC>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCED PLATELET-AGGREGATION; MEMBRANE GLYCOPROTEIN-IIB; CYCLIC FLOW VARIATIONS; ADENOSINE-DIPHOSPHATE; ARTERIAL THROMBOSIS; ADENYLATE-CYCLASE; RAT PLATELETS; THIENOPYRIDINE CLOPIDOGREL; CALCIUM MOBILIZATION; IIIA COMPLEX;
Keywords:
ADP; clopidogrel; platelet aggregation; thrombosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
86
Recensione:
Indirizzi per estratti:
Indirizzo: Herbert, JM SanofieRech, Haemobiol Res Dept, 195 Route Espagne, F-31036 Toulouse, Franc Sanofi Rech 195 Route Espagne Toulouse France F-31036 , Franc
Citazione:
J.M. Herbert et al., "Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist", EUR H J SUP, 1(A), 1999, pp. A31-A40

Abstract

Clopidogrel is a novel platelet ADP receptor antagonist. Animal experiments have shown that clopidogrel's antiaggregating activity is due to a short-lasting metabolite generated in the liver by a cytochrome P-450-dependent pathway. The active metabolite of clopidogrel antagonizes a set of low-affinity ADP receptors on platelets. Thus, clopidogrel therapy inhibits adenylylcyclase down regulation, protein phosphorylation at tyrosine residues, Gp IIb/IIIa complex activation, and fibrinogen binding, aggregation and release. This suggests that these processes are mediated by activation of the low-affinity ADP receptor. Clopidogrel therapy reduces the platelet aggregation and myointimal thickening that occur following endothelial injury of the rabbit carotid artery. The antithrombotic activity of clopidogrel is several times greater than that of ticlopidine and aspirin in animal models of arterial and venous thrombosis. Clopidogrel is more effective than aspirin and has a favourable safety and tolerability profile; thus, it is a promisingand potent antithrombotic therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 02:52:42